| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM200108023450502 |
| P698 | PubMed publication ID | 11484688 |
| P2093 | author name string | Newman JH | |
| Wheeler L | |||
| Loyd JE | |||
| Phillips JA 3rd | |||
| Lane KB | |||
| Gaddipati R | |||
| Loyd E | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | primary pulmonary hypertension | Q18554794 |
| morphogenesis | Q815547 | ||
| P1104 | number of pages | 6 | |
| P304 | page(s) | 319-324 | |
| P577 | publication date | 2001-08-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred | |
| P478 | volume | 345 |
| Q88690808 | A Review of Transcriptome Analysis in Pulmonary Vascular Diseases |
| Q30544892 | A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects |
| Q37359026 | A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension |
| Q33970081 | A novel BMPR2 mutation associated with pulmonary arterial hypertension in an octogenarian |
| Q51192735 | A novel break point of the BMPR2 gene exonic deletion in a patient with pulmonary arterial hypertension. |
| Q37104263 | A potential role for insulin resistance in experimental pulmonary hypertension |
| Q42340418 | A review of pulmonary arterial hypertension: Part 1. Novel insights and classification |
| Q35600688 | Activation of K+ channels: an essential pathway in programmed cell death |
| Q37755020 | Advances in therapies for pediatric pulmonary arterial hypertension |
| Q80094203 | Association of HLA class II genes with idiopathic pulmonary arterial hypertension in Koreans |
| Q47948580 | BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia |
| Q38799538 | BMPR2 gene therapy for PAH acts via Smad and non-Smad signalling. |
| Q31038850 | BMPR2 revisited: are bigger data better? |
| Q36185917 | Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension |
| Q46515326 | Bone morphogenetic protein-2 upregulates expression and function of voltage-gated K+ channels in human pulmonary artery smooth muscle cells |
| Q73376498 | Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells |
| Q24791993 | Bone morphogenetic proteins, genetics and the pathophysiology of primary pulmonary hypertension |
| Q35005853 | Building the case for novel clinical trials in pulmonary arterial hypertension |
| Q26766294 | Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs |
| Q34199837 | Chronic allergic inflammation causes vascular remodeling and pulmonary hypertension in BMPR2 hypomorph and wild-type mice |
| Q55286562 | Clinical and genetic characteristics of pulmonary arterial hypertension in Lebanon. |
| Q44096475 | Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. |
| Q39021300 | Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. |
| Q33155179 | Clinical presentation, differential diagnosis, and vasodilator testing of pulmonary hypertension |
| Q35024562 | Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats |
| Q35412283 | Combination use of sildenafil and simvastatin increases BMPR-II signal transduction in rats with monocrotaline-mediated pulmonary hypertension |
| Q38450447 | Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension |
| Q35673783 | Current clinical management of pulmonary arterial hypertension |
| Q36225802 | Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension |
| Q33786374 | Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease |
| Q44180844 | Dexfenfluramine protects against pulmonary hypertension in rats |
| Q39010196 | Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era: A Review |
| Q44407006 | Disease-associated mutations in conserved residues of ALK-1 kinase domain |
| Q28572271 | Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension |
| Q37394425 | EIF2AK4 mutation as "second hit" in hereditary pulmonary arterial hypertension |
| Q36940790 | Eisenmenger syndrome and atrial septal defect: nature or nurture? |
| Q44487846 | Emerging therapies for pulmonary hypertension: striving for efficacy and safety |
| Q34631613 | Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension |
| Q37901411 | From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension |
| Q36934968 | Functional redundancy of type II BMP receptor and type IIB activin receptor in BMP2-induced osteoblast differentiation |
| Q33372590 | Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance |
| Q37827155 | Gene therapy for pulmonary hypertension: prospects and challenges |
| Q34801954 | Genetic counselling for pulmonary arterial hypertension: a matter of variable variability |
| Q24806161 | Genetic epidemiology: systemic sclerosis |
| Q37051037 | Genetics and genomics of pulmonary arterial hypertension |
| Q36752306 | Genetics and mediators in pulmonary arterial hypertension |
| Q34394986 | Genetics of primary pulmonary hypertension |
| Q34420043 | Genomics and proteomics of lung disease: conference summary |
| Q36016529 | HIV protease inhibitors in pulmonary hypertension: rationale and design of a pilot trial in idiopathic pulmonary arterial hypertension |
| Q91651407 | HYAL1 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits HFL-1 Fibroblast Proliferation When Upregulated |
| Q33761721 | Heart failure and pulmonary hypertension |
| Q42540943 | High-altitude pulmonary hypertension in cattle (brisket disease): Candidate genes and gene expression profiling of peripheral blood mononuclear cells |
| Q35217383 | Human immunodeficiency virus transgenic rats exhibit pulmonary hypertension |
| Q39150404 | Hypoxia downregulates PPARγ via an ERK1/2-NF-κB-Nox4-dependent mechanism in human pulmonary artery smooth muscle cells |
| Q58730399 | Identification of a low frequency missense mutation in MUC6 contributing to pulmonary artery hypertension by whole-exome sequencing |
| Q33788452 | Identifying "super responders" in pulmonary arterial hypertension. |
| Q28590362 | Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice |
| Q92189114 | Joint Transcriptomic Analysis of Lung Cancer and Other Lung Diseases |
| Q35136658 | Kinase activity profiling of gram-negative pneumonia |
| Q28361811 | Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension |
| Q93204496 | Long non-coding RNAs influence the transcriptome in pulmonary arterial hypertension: the role of PAXIP1-AS1 |
| Q36488756 | Longitudinal analysis casts doubt on the presence of genetic anticipation in heritable pulmonary arterial hypertension. |
| Q47449827 | Loss of SMAD3 Promotes Vascular Remodeling in Pulmonary Arterial Hypertension via MRTF Disinhibition |
| Q39673639 | Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and Group III pulmonary hypertension |
| Q36477935 | Mediators and modulators of pulmonary arterial hypertension |
| Q38679814 | MicroRNA in the Diseased Pulmonary Vasculature: Implications for the Basic Scientist and Clinician. |
| Q37308092 | MicroRNAs in pulmonary arterial remodeling |
| Q34576173 | Modification of hemodynamic and immune responses to exposure with a weak antigen by the expression of a hypomorphic BMPR2 gene |
| Q36943272 | Monocrotaline pyrrole induces Smad nuclear accumulation and altered signaling expression in human pulmonary arterial endothelial cells |
| Q36606635 | Mutations of TGFbeta signaling molecules in human disease |
| Q52997994 | Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. |
| Q34782501 | Myosin heavy chain 15 is associated with bovine pulmonary arterial pressure |
| Q64911746 | New cases of Glucose-6-Phosphate Dehydrogenase deficiency in Pulmonary Arterial Hypertension. |
| Q34625826 | New treatments for pulmonary arterial hypertension |
| Q35750204 | Nitric oxide and other novel therapies for pulmonary hypertension |
| Q35165691 | Non-congenital heart disease associated pediatric pulmonary arterial hypertension |
| Q57091338 | Novel insight into the genetic basis of high-altitude pulmonary hypertension in Kyrgyz highlanders |
| Q26821779 | Pathobiology of pulmonary arterial hypertension and right ventricular failure |
| Q36447388 | Pathogenic mechanisms of pulmonary arterial hypertension |
| Q37144624 | Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele |
| Q46686053 | Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation |
| Q24633128 | Preparing for the first breath: genetic and cellular mechanisms in lung development |
| Q73370839 | Primary pulmonary hypertension |
| Q37084786 | Pulmonary arterial hypertension from a pediatric perspective |
| Q34950123 | Pulmonary arterial hypertension in congenital heart disease |
| Q36834617 | Pulmonary arterial hypertension: an overview |
| Q37671277 | Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response |
| Q38155079 | Pulmonary arterial hypertension: challenges in translational research and a vision for change |
| Q74117447 | Pulmonary hypertension: current criteria for diagnosis and treatment |
| Q35192891 | Pulmonary hypertension: work in progress |
| Q27687091 | Pulmonary vascular disease related to hemodynamic stress in the pulmonary circulation |
| Q41181690 | Pulmonary vascular diseases: in search of a hub among the spokes-an exercise in hypothesis generation |
| Q44225835 | Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. |
| Q34383236 | Rat strain differences in pulmonary artery smooth muscle Ca(2+) entry following chronic hypoxia |
| Q38027723 | Regulatory T cells and pulmonary hypertension |
| Q38870144 | Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. |
| Q44593177 | Retinal diseases with primary pulmonary hypertension |
| Q35905574 | Reversal of MicroRNA Dysregulation in an Animal Model of Pulmonary Hypertension |
| Q55119395 | Reversible pulmonary artery perfusion abnormalities in the postpartum period as a precursor to the development of pulmonary arterial hypertension. |
| Q36596818 | Review of bosentan in the management of pulmonary arterial hypertension |
| Q37898745 | Rodent models of pulmonary hypertension: harmonisation with the world health organisation's categorisation of human PH. |
| Q33959437 | Role of BMPR2 alternative splicing in heritable pulmonary arterial hypertension penetrance. |
| Q28078566 | Role of oxidized lipids in pulmonary arterial hypertension |
| Q36605656 | Role of the endothelium in pulmonary arterial hypertension |
| Q33965854 | Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Genetics of pulmonary hypertension |
| Q34973575 | Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH. |
| Q35280612 | Severe paediatric pulmonary hypertension: new management strategies |
| Q44198491 | Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. |
| Q35573926 | Surgical treatment of pulmonary hypertension: Lung transplantation |
| Q36340862 | TRAIL: not just for tumors anymore? |
| Q37346515 | The 'sweet' and 'bitter' involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance |
| Q28570134 | The BMP type II receptor is located in lipid rafts, including caveolae, of pulmonary endothelium in vivo and in vitro |
| Q26744761 | The Role of Hyperglycemia and Insulin Resistance in the Development and Progression of Pulmonary Arterial Hypertension |
| Q45046014 | The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension |
| Q36023813 | The biological "scrabble" of pulmonary arteriovenous malformations: considerations in the setting of cavopulmonary surgery |
| Q44693038 | The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux |
| Q35168404 | The endothelin system in pulmonary hypertension. |
| Q78348661 | The genetics of congenital heart disease: a point in the revolution |
| Q37782012 | The role of mitochondria in pulmonary vascular remodeling |
| Q35925357 | The role of peroxisome proliferator-activated receptors in pulmonary vascular disease |
| Q37090543 | Transcripts from a novel BMPR2 termination mutation escape nonsense mediated decay by downstream translation re-initiation: implications for treating pulmonary hypertension |
| Q50476552 | Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension |
| Q49312062 | Translational Advances in the Field of Pulmonary Hypertension. Translating MicroRNA Biology in Pulmonary Hypertension. It Will Take More Than "miR" Words |
| Q42782703 | Treatment of pulmonary hypertension |
| Q34985847 | Treatment of pulmonary hypertension: a promising new age. |
| Q37389602 | Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension |
| Q64939788 | United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. |
| Q35916971 | Use of myocardial performance index in pediatric patients with idiopathic pulmonary arterial hypertension |
| Q55286414 | Using Omics to Understand and Treat Pulmonary Vascular Disease. |
| Q21245270 | Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals |
| Q35443190 | Visceral manifestations in hereditary haemorrhagic telangiectasia type 2 |
| Q73511259 | [Consensus recommendations of the Pulmonary Arterial Hypertension Study Group of the Austrian Society of Lung Diseases and Tuberculosis] |
| Q80393837 | [Endothelial dysfunction in pulmonary hypertension] |
| Q79804168 | [Pulmonary arterial hypertension in collagenoses: clinical features, epidemiology, pathogenesis, diagnosis and treatment] |
| Q64279035 | ＜Editors' Choice＞ Pulmonary Hypertension: Diagnosis, Management, and Treatment |
Search more.